Publication | Closed Access
Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance.
408
Citations
17
References
1985
Year
GynecologyPathologyMultidrug ResistanceCancer BiologyTumor BiologyOvarian CancerDrug ResistanceOncologyMolecular DiagnosticsMolecular OncologyMonoclonal AntibodyDrug Resistance AnalysisOncogenic AgentCell-surface GlycoproteinCancer TreatmentPharmacologyMalignant DiseaseMolecular MarkerTumor MicroenvironmentEndocrine-related CancerMedicine
A multidrug resistance phenotype is frequently observed in animal and human cell lines selected for in vitro resistance to a single chemotherapeutic agent. Overexpression of a highly conserved cell-surface glycoprotein (P-glycoprotein) is consistently associated with this phenotype in these mutant lines. A monoclonal antibody against P-glycoprotein was used to examine tumor samples from five patients with advanced ovarian cancer for evidence of P-glycoprotein overexpression. High levels of P-glycoprotein were detected in samples from two patients suggesting that a multidrug resistance mutation may also occur in ovarian cancer. This finding has broad implications for the understanding of nonresponse to chemotherapy in a variety of human neoplasms, and may provide a rational explanation for failure of chemotherapy in treatment of advanced ovarian cancer.
| Year | Citations | |
|---|---|---|
Page 1
Page 1